Sign In
Last checked at 
28 Apr 2023 17:01
GSK plc (the 'Company')
2023 Performance Share Plan Award - Ms J Brown, CFO Designate
2023 Performance Share Plan Award
On 27 April 2023, the Company granted conditional share awards to Ms Julie Brown, a Person Discharging Managerial Responsibilities ('PDMR') under the GlaxoSmithKline 2017 Performance Share Plan ('the Plan'). The Plan was approved by shareholders on 4 May 2017 and allows a performance-related opportunity in the form of conditional awards to be granted to senior executives in the Group, including Executive Directors and other PDMRs.
Under the terms of the Plan, conditional awards are granted over a specific number of Ordinary Shares or American Depositary Shares ('ADSs'), and the percentage of awards that ultimately vests is dependent on the level of achievement against performance targets set by the Remuneration Committee.
28 April 2023
Notes
1. See the announcement released on 14 February 2023 ('2023 Performance Share Plan Award and 2023 Performance Measures') for details of the 2023 performance measures.
2. To the extent that each element of a conditional award does not vest at the end of the three-year performance period, it will lapse.
3. The Award granted to Ms Brown is over Ordinary Shares.
4. Dividends will accrue on the conditional award of Ordinary Shares during the performance period but will only vest to the extent that the award vests at the end of the performance period. These dividends are not included in the figures below.
5. The award is subject to an additional vesting period of two years (the 'Holding Period') from the normal vesting date, i.e. five years in total. During the additional Holding Period, the relevant Ordinary Shares would only be forfeited in the event that the Executive Director was terminated for cause, and the Ordinary Shares will continue to carry rights to dividend equivalents.
Transaction notification
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Ms J Brown | |||
b) | Position/status | CFO Designate | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 | |||
b) | Nature of the transaction | A conditional award of Ordinary Shares under the Company's 2017 Performance Share Plan | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£14.422 | 264,026 | ||||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2023-04-27 | |||
f) | Place of the transaction
| N/A | |||
Follow the stocks
